{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:35:00Z","timestamp":1770824100753,"version":"3.50.1"},"reference-count":156,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2002,10,1]],"date-time":"2002-10-01T00:00:00Z","timestamp":1033430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2002,10,1]],"date-time":"2002-10-01T00:00:00Z","timestamp":1033430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2002,10]]},"DOI":"10.1016\/s0889-8588(02)00050-3","type":"journal-article","created":{"date-parts":[[2005,4,18]],"date-time":"2005-04-18T10:53:30Z","timestamp":1113821610000},"page":"1065-1088","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Inhibitors of the ras oncogene as therapeutic targets"],"prefix":"10.1016","volume":"16","author":[{"given":"Irene M","family":"Ghobrial","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex A","family":"Adjei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/S0889-8588(02)00050-3_BIB1","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1093\/jnci\/93.14.1062","article-title":"Blocking oncogenic Ras signaling for cancer therapy","volume":"193","author":"Adjei","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB2","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.2174\/1381612013397258","article-title":"Ras signaling pathway proteins as therapeutic targets","volume":"7","author":"Adjei","year":"2001","journal-title":"Current Pharm Design"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB3","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1146\/annurev.bi.56.070187.004023","article-title":"Ras genes","volume":"56","author":"Barbacid","year":"1987","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB4","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0168-9525(98)01592-3","article-title":"Genetics of RAS signaling in C. elegans","volume":"14","author":"Sternberg","year":"1998","journal-title":"Trends Genet"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB5","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0955-0674(99)00071-X","article-title":"The ras branch of small GTPases: ras family members don't fall far from the tree","volume":"12","author":"Reuther","year":"2000","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB6","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/sj.onc.1202174","article-title":"Increasing complexity of Ras signaling","volume":"17","author":"Campbell","year":"1998","journal-title":"Oncogene"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB7","first-page":"625","article-title":"The ras superfamily of small GTPases","volume":"10","author":"Macara","year":"1996","journal-title":"Fed Am Soc Exper Biol J"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB8","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/343425a0","article-title":"Regulation of the mevalonate pathway","volume":"343","author":"Goldstein","year":"1990","journal-title":"Nature"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB9","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1146\/annurev.bi.65.070196.001325","article-title":"Protein prenylation: molecular mechanisms and functional consequences","volume":"65","author":"Zhang","year":"1996","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB10","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1146\/annurev.bi.61.070192.002035","article-title":"Protein isoprenylation and methylation at carboxyl-terminal cysteine residues","volume":"61","author":"Clarke","year":"1992","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB11","doi-asserted-by":"crossref","first-page":"6403","DOI":"10.1073\/pnas.89.14.6403","article-title":"Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity","volume":"89","author":"Kato","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB12","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1073\/pnas.85.13.4643","article-title":"Posttranslational modification of the Ha-ras oncogene protein: evidence for a third class of protein carboxyl methyltransferases","volume":"85","author":"Clarke","year":"1988","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB13","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/j.1460-2075.1991.tb07992.x","article-title":"Methylation and proteolysis are essential for efficient membrane binding of prenylated p21K-ras(B)","volume":"10","author":"Hancock","year":"1991","journal-title":"EMBO J"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB14","doi-asserted-by":"crossref","first-page":"20422","DOI":"10.1016\/S0021-9258(19)47079-8","article-title":"Human lamin B contains a farnesylated cysteine residue","volume":"264","author":"Farnsworth","year":"1989","journal-title":"J Biol Chem"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1242\/jcs.107.1.61","article-title":"The processing pathway of prelamin A","volume":"107","author":"Sinensky","year":"1994","journal-title":"J Cell Sci"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB16","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0021-9258(18)48336-6","article-title":"In vivo differential prenylation of retinal cyclic GMP phosphodiesterase catalytic subunits","volume":"267","author":"Anant","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB17","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0021-9258(18)45960-1","article-title":"Isoprenyaltion of a protein kinase: requirement of farnesylation\/alpha-carboxylmethylation for full enzymatic activity of rhodopsin kinase","volume":"267","author":"Inglese","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB18","doi-asserted-by":"crossref","first-page":"14182","DOI":"10.1016\/S0021-9258(17)36772-8","article-title":"PxF, a prenylated protein of peroxisomes","volume":"269","author":"James","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB19","doi-asserted-by":"crossref","first-page":"7673","DOI":"10.1073\/pnas.87.19.7673","article-title":"The gamma subunit of transducin is farnesylated","volume":"87","author":"Lai","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB20","first-page":"1400","article-title":"Structure and biological activity of human homologs of the raf\/mil oncogene","volume":"5","author":"Bonner","year":"1985","journal-title":"Mol Cell Biol"},{"issue":"Suppl","key":"10.1016\/S0889-8588(02)00050-3_BIB21","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1007\/s002800051075","article-title":"Clinical evaluation of biologically targeted drugs: obstacles and opportunities","volume":"42","author":"Boral","year":"1998","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB22","doi-asserted-by":"crossref","first-page":"8631","DOI":"10.1073\/pnas.88.19.8631","article-title":"Enzymatic modification of proteins with a geranylgeranyl isoprenoid","volume":"88","author":"Casey","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB23","doi-asserted-by":"crossref","first-page":"5302","DOI":"10.1073\/pnas.88.12.5302","article-title":"A protein geranylgeranyltransferase from bovine brain: implications for protein prenylation specificity","volume":"88","author":"Yokoyama","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB24","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1093\/emboj\/17.12.3351","article-title":"The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus","volume":"17","author":"Strong","year":"1998","journal-title":"EMBO J"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB25","doi-asserted-by":"crossref","first-page":"14497","DOI":"10.1016\/S0021-9258(19)49740-8","article-title":"Rab geranylgeranyl transferase: a multisubunit enzyme that prenylates GTP-binding proteins terminating in Cys-X-Cys or Cys-Cys","volume":"267","author":"Seabra","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB26","doi-asserted-by":"crossref","first-page":"11963","DOI":"10.1073\/pnas.91.25.11963","article-title":"Rab geranylgeranyl transferase catalyzes the geranylgeranylation of adjacent cysteines in the small GTPases Rab1A, Rab3A, and Rab5A","volume":"91","author":"Farnsworth","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB27","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00001813-200103000-00001","article-title":"Ras biochemistry and farnesyl transferase inhibitors: a literature survey","volume":"12","author":"Crul","year":"2001","journal-title":"Anticancer Drugs"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB28","first-page":"1","article-title":"Signal transduction therapy. a novel approach to disease management","volume":"226","author":"Levitzki","year":"1994","journal-title":"Eur J Biochem"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB29","first-page":"669","article-title":"Integrin functions and signal transduction","volume":"400B","author":"Aota","year":"1997","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB30","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/sj.onc.1202172","article-title":"Signaling by integrin receptors","volume":"17","author":"Kumar","year":"1998","journal-title":"Oncogene"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB31","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/jcb.240540408","article-title":"How does the g protein, Gi2 transduce mitogenic signals?","volume":"54","author":"Johnson","year":"1994","journal-title":"J Cell Biochem"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB32","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1073\/pnas.88.8.3314","article-title":"Involvement of ras p21 protein in signal \u2013transduction pathways from interleukin2, interleukin 3, and granulocyte\/macrophage colony stimulating factor, but not from interleukin4","volume":"88","author":"Satoh","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB33","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1073\/pnas.89.5.1587","article-title":"P21 ras activation via hemopoietin receptors and c-kit requires tyrosine kinase activity but not tyrosine phosphorylation of p21 ras GTPase-activating protein","volume":"89","author":"Duronio","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB34","doi-asserted-by":"crossref","first-page":"19448","DOI":"10.1016\/S0021-9258(18)41796-6","article-title":"Differentiation factors, including nerve growth factor, fibroblast growth factor, and interleukin-6, induce an accumulation of an active ras.GTP complex in rat pheochromocytome PC12 cells","volume":"267","author":"Nakafuku","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB35","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/366643a0","article-title":"Proteins regulating Ras and its relatives","volume":"366","author":"Boguski","year":"1993","journal-title":"Nature"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB36","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/bies.950160708","article-title":"Regulation of the Ras signalling network","volume":"16","author":"Maruta","year":"1994","journal-title":"Bioessays"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB37","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/373573a0","article-title":"Protein modules and signaling networks","volume":"373","author":"Pawson","year":"1995","journal-title":"Nature"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB38","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/376527a0","article-title":"Identification of a specific Ins(1,3,4,5)P4-binding protein as a member of the GAP1 family","volume":"376","author":"Cullen","year":"1995","journal-title":"Nature"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB39","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1128\/MCB.15.3.1318","article-title":"A human protein selected for interference with Ras function interacts directly with Ras and competes with Raf1","volume":"15","author":"Han","year":"1995","journal-title":"Mol Cell Biol"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB40","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/0888-7543(91)90017-9","article-title":"cDNA cloning of the type 1 neurofibromatosis gene: complete sequence of the NF1 gene product","volume":"11","author":"Marchuk","year":"1991","journal-title":"Genomics"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB41","doi-asserted-by":"crossref","first-page":"9914","DOI":"10.1073\/pnas.88.22.9914","article-title":"Identification and characterization of the neurofibromatosis type 1 protein product","volume":"88","author":"DeClue","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB42","first-page":"57","article-title":"Increasing complexity of Ras signal transduction: involvement of Rho family proteins","volume":"72","author":"Khosravi-Far","year":"1998","journal-title":"Adv Cancer Res"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB43","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1126\/science.8052857","article-title":"Transformation of mammalian cells by constitutively active MAP kinase kinase","volume":"265","author":"Mansour","year":"1994","journal-title":"Science"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB44","doi-asserted-by":"crossref","first-page":"31706","DOI":"10.1016\/S0021-9258(18)31753-8","article-title":"Evidence for the in vitro and in vivo interaction of Ras with protein kinase C zeta","volume":"269","author":"Diaz-Meco","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB45","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1074\/jbc.271.2.607","article-title":"Identification of AF-6 and Canoe as putative targets for Ras","volume":"271","author":"Kuriyama","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB46","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.7811320","article-title":"Activation of Raf as a result of recruitment to the plasma membrane","volume":"264","author":"Stokoe","year":"1994","journal-title":"Science"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB47","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S0955-0674(97)80060-9","article-title":"The complexity of Raf-1 regulation","volume":"9","author":"Morrison","year":"1997","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB48","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/383127a0","article-title":"Cell signalling: Raf gets it together","volume":"383","author":"Marshall","year":"1996","journal-title":"Nature"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB49","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1038\/sj.onc.1201582","article-title":"Membrane recruitment of Raf-1 is not the only function of Ras in Raf-1 activation","volume":"15","author":"Tamada","year":"1997","journal-title":"Oncogene"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB50","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/369411a0","article-title":"Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane","volume":"369","author":"Leevers","year":"1994","journal-title":"Nature"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB51","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/ng0797-214","article-title":"Raf revealed in life-or-death decisions","volume":"16","author":"Pritchard","year":"1997","journal-title":"Nat Genet"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB52","first-page":"639","article-title":"Definition of the human raf amino-terminal regulatory region by deletion mutagenesis","volume":"9","author":"Stanton","year":"1989","journal-title":"Mol Cell Biol"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB53","first-page":"2503","article-title":"Mutational activation of c-raf-1 and definition of the minimal transforming sequence","volume":"10","author":"Heidecker","year":"1990","journal-title":"Mol Cell Biol"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB54","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0968-0004(00)88944-6","article-title":"Regulation of Ras-mediated signaling: more than one way to skin a cat","volume":"20","author":"Burgering","year":"1995","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB55","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/349426a0","article-title":"Raf-1 protein kinase is required for growth of induced NIH\/3T3 cells","volume":"349","author":"Kolch","year":"1991","journal-title":"Nature"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB56","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/0092-8674(94)90133-3","article-title":"Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells","volume":"77","author":"Cowley","year":"1994","journal-title":"Cell"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB57","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1128\/MCB.17.6.3047","article-title":"Interaction of activated Ras with Raf-1 alone may be sufficient for transformation of rat2 cells","volume":"7","author":"Stang","year":"1997","journal-title":"Mol Cell Biol"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB58","doi-asserted-by":"crossref","first-page":"20232","DOI":"10.1016\/S0021-9258(20)80719-4","article-title":"A dominant-negative mutant of raf blocks mitogen-activated protein kinase activation by growth factors and oncogenic p21ras","volume":"268","author":"Schaap","year":"1993","journal-title":"J Biol Chem"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB59","first-page":"2281","article-title":"Identification of binding domains on the p21cip1 cycli-dependent kinase inhibitor","volume":"10","author":"Goubin","year":"1995","journal-title":"Oncogene"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB60","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1101\/gad.11.5.663","article-title":"Cooperating oncogenes converge to regulate cyclin\/cdk complexes","volume":"11","author":"Lloyd","year":"1997","journal-title":"Genes Dev"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB61","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.1128\/MCB.17.9.5598","article-title":"Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21cip1","volume":"17","author":"Woods","year":"1997","journal-title":"Mol Cell Biol"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB62","first-page":"2289","article-title":"Critical role of Rho in cell transformation by oncogenic Ras","volume":"10","author":"Prendergast","year":"1995","journal-title":"Oncogene"},{"issue":"Suppl 1","key":"10.1016\/S0889-8588(02)00050-3_BIB63","first-page":"25","article-title":"Signal transduction pathways regulated by the Rho family of small GTPases","volume":"80","author":"Hall","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB64","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1146\/annurev.biochem.68.1.459","article-title":"Regulation of the cytoskeleton and cell adhesion by the Rho family GTPases in mammalian cells","volume":"68","author":"Kaibuchi","year":"1999","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB65","doi-asserted-by":"crossref","first-page":"11781","DOI":"10.1073\/pnas.92.25.11781","article-title":"A role for Rho in ras transformation","volume":"92","author":"Qiu","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB66","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1126\/science.279.5350.509","article-title":"Rho GTPases and the actin cytoskeleton","volume":"279","author":"Hall","year":"1998","journal-title":"Science"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB67","first-page":"457","article-title":"Phosphatidylinositol-3-OH kinase as a direct target of Ras","volume":"89","author":"Rodriguez Viciana","year":"1997","journal-title":"Cell"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB68","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0955-0674(96)80060-3","article-title":"Phosphoinositide kinases","volume":"8","author":"Carpenter","year":"1996","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB69","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1126\/science.282.5392.1318","article-title":"Regulation of cell death protease caspase-9 by phosphorylation","volume":"282","author":"Cardone","year":"1998","journal-title":"Science"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB70","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0092-8674(00)80405-5","article-title":"Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery","volume":"91","author":"Datta","year":"1997","journal-title":"Cell"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB71","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/376599a0","article-title":"Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction","volume":"376","author":"Burgering","year":"1995","journal-title":"Nature"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB72","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/0092-8674(95)90534-0","article-title":"The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase","volume":"81","author":"Franke","year":"1995","journal-title":"Cell"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB73","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1101\/gad.13.11.1422","article-title":"Regulation of 4E\u2013BP1 phosphorylation: a novel two-step mechanism","volume":"13","author":"Gingras","year":"1999","journal-title":"Genes Dev"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB74","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1357-2725(98)00131-9","article-title":"eIF4E activity is regulated at multiple levels","volume":"31","author":"Raught","year":"1999","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB75","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1073\/pnas.95.4.1432","article-title":"RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E\u2013BP1","volume":"95","author":"Burnett","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB76","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1128\/MCB.17.2.862","article-title":"Nf1-deficient mouse Schwann cells are angiogenic and invasive and can be induced to hyperproliferate: reversion of some phenotypes by an inhibitor of farnesyl protein transferase","volume":"17","author":"Kim","year":"1997","journal-title":"Mol Cell Biol"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB77","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/ng0296-144","article-title":"Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells","volume":"12","author":"Bollag","year":"1996","journal-title":"Nat Genet"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB78","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/377695a0","article-title":"Vascular system defects and neuronal apoptosis in mice lacking ras GTPas-activating protein","volume":"377","author":"Henkenmeyer","year":"1995","journal-title":"Nature"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB79","doi-asserted-by":"crossref","first-page":"16439","DOI":"10.1074\/jbc.271.28.16439","article-title":"A role for the Ral guanine nucleotide dissociation stimulator in mediating Ras-induced transformation","volume":"271","author":"White","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB80","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1038\/sj.onc.1201473","article-title":"Colocalization of Ras and Ral on the membrane is required for Ras-dependent Ral activation through Ral GDP dissociation stimulator","volume":"15","author":"Kishida","year":"1997","journal-title":"Oncogene"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB81","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/j.1460-2075.1993.tb05662.x","article-title":"Characterization of a guanine nucleotide dissociation stimulator for a ras-related GTPase","volume":"12","author":"Albright","year":"1993","journal-title":"EMBO J"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB82","first-page":"7483","article-title":"Characterization of a guanine nucleotide dissociation stimulator for a ras-related GTPase","volume":"14","author":"Kikuchi","year":"1994","journal-title":"Mol Cell Biol"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB83","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1016\/S0960-894X(98)00439-9","article-title":"Inhibitors of farnesyl protein transferase: synthesis and biological activity of amide and cyanoguanidine derivatives containing a 5,11-dihydro[1]benzthiepin, benzoxepin, and benzazepin [4,3-b]pyridine ring system","volume":"8","author":"Wolin","year":"1998","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB84","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/sj.onc.1200950","article-title":"Rsc: a novel oncogene with structural and functional homology with the gene family of exchange factors for Ral","volume":"14","author":"D'Adamo","year":"1997","journal-title":"Oncogene"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB85","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1126\/science.271.5250.810","article-title":"Stimulation of membrane ruffling and MAP kinase activation by distinct effectors of RAS","volume":"271","author":"Joneson","year":"1996","journal-title":"Science"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB86","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0960-9822(98)70183-6","article-title":"Ras-dependent activation of the small GTPase Ral","volume":"8","author":"Wolthuis","year":"1998","journal-title":"Curr Biol"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB87","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1126\/science.8073291","article-title":"Ras-dependent growth factor regulation of MEK kinase in PC12 cells","volume":"265","author":"Lange-Carter","year":"1994","journal-title":"Science"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB88","doi-asserted-by":"crossref","first-page":"16483","DOI":"10.1074\/jbc.270.28.16483","article-title":"The regulation of AP-1 activity by mitogen-activated protein kinases","volume":"270","author":"Karin","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB89","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJM199508033330508","article-title":"Oncogenes","volume":"333","author":"Krontiris","year":"1995","journal-title":"N Eng J Med"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB90","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1073\/pnas.94.2.448","article-title":"Cell cycle arrest mediated by the MEK\/mitogen-activated protein kinase pathway","volume":"94","author":"Pumiglia","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB91","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1182\/blood.V96.5.1655","article-title":"Targeting the ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?","volume":"96","author":"Reuter","year":"2000","journal-title":"Blood"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB92","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/327293a0","article-title":"Prevalence of ras gene mutations in colorectal cancers","volume":"327","author":"Bos","year":"1987","journal-title":"Nature"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB93","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1056\/NEJM198809013190901","article-title":"Genetic alterations during colorectal-tumor development","volume":"319","author":"Vogelstein","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB94","first-page":"4682","article-title":"Ras oncogenes in human cancer: a review","volume":"49","author":"Bos","year":"1989","journal-title":"Cancer Res"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB95","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1517\/13543784.8.12.2121","article-title":"Concepts in Ras-directed therapy","volume":"8","author":"Kloog","year":"1999","journal-title":"Exp Opin Invest Drugs"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB96","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/300149a0","article-title":"A point mutation is responsible for the acquisition of transforming properties by T24 human bladder carcinoma oncogene","volume":"300","author":"Reddy","year":"1982","journal-title":"Nature"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB97","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/300762a0","article-title":"Activation of the T24 bladder carcinoma transforming gene is linked to a single amino acid change","volume":"300","author":"Taparowsky","year":"1982","journal-title":"Nature"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB98","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/300143a0","article-title":"Mechanism of activation of a human oncogene","volume":"300","author":"Tabin","year":"1982","journal-title":"Nature"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB99","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1365-2362.1990.tb01848.x","article-title":"Ras oncogenes: their role in neoplasia","volume":"20","author":"Barbacid","year":"1990","journal-title":"Eur J Clin Inv"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB100","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/309464a0","article-title":"Ha-ras oncogenes are activated by somatic alterations in urinary tract tumors","volume":"309","author":"Fujita","year":"1984","journal-title":"Nature"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB101","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood.V91.1.3","article-title":"Multiple myeloma: increasing evidence of a multistep transformation process","volume":"91","author":"Hallek","year":"1998","journal-title":"Blood"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB102","first-page":"77","article-title":"Preferential and novel activation of H-ras in human bladder carcinomas","volume":"3","author":"Visvanathan","year":"1988","journal-title":"Oncogene Res"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB103","first-page":"296","article-title":"Growth inhibitory effect of anti-K-ras adenovirus on lung cancer cells","volume":"3","author":"Alemany","year":"1996","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB104","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1126\/science.282.5392.1332","article-title":"Reovirus therapy of tumors with activated Ras pathway","volume":"282","author":"Coffey","year":"1998","journal-title":"Science"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB105","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1126\/science.3277276","article-title":"The ras incogenes increase the intrinsic resistance of NIH3T3 cells to ionizing radiation","volume":"239","author":"Sklar","year":"1988","journal-title":"Science"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB106","first-page":"97","article-title":"Synergistic effect of the v-myc oncogene with H-ras on radioresistance","volume":"50","author":"McKenna","year":"1990","journal-title":"Cancer Res"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB107","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1023\/A:1006380320290","article-title":"Farnesyl protein transferase inhibitors and other therapies targeting the ras signal transduction pathway","volume":"17","author":"End","year":"2000","journal-title":"Invest New Drugs"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB108","first-page":"5302","article-title":"A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines","volume":"55","author":"Sepp-Lorenzino","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB109","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1517\/13543784.10.12.2059","article-title":"Novel pharmacological agents in clinical development for solid tumors","volume":"10","author":"Dy","year":"2001","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB110","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/00001622-200111000-00009","article-title":"Current status of clinical trials of farnesyltransferase inhibitors","volume":"13","author":"Karp","year":"2001","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB111","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1161\/01.ATV.17.5.898","article-title":"Adenovirus-mediated transfer of a dominant-negative H-ras suppresses neointimal formation in balloon-injured arteries in vivo","volume":"17","author":"Ueno","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB112","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1089\/hum.1993.4.4-451","article-title":"Retroviral vector-mediated transduction of K-ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype","volume":"4","author":"Zhang","year":"1993","journal-title":"Human Gene Ther"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB113","first-page":"1743","article-title":"Prevention of orthotopic human lung cancer growth by intratracheal instillation of a retroviral antisense K-ras construct","volume":"53","author":"Georges","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB114","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/(SICI)1098-2744(199710)20:2<251::AID-MC12>3.0.CO;2-9","article-title":"Suppression of Ki-ras p21 levels leading to growth inhibition of pancreatic cancer cell lines with Ki-ras mutation but not those without Ki-ras mutation","volume":"20","author":"Aoki","year":"1997","journal-title":"Mol Carcinog"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB115","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1089\/oli.1.1997.7.71","article-title":"Comparative pharmacokinetics, tissue distribution, and tumor accumulation of phosphorothioate, phosphorodithioate, and methylphosphonate oligonucleotides in nude mice","volume":"7","author":"DeLong","year":"1997","journal-title":"Antisense Nucleic Acid Drug Dev"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB116","doi-asserted-by":"crossref","first-page":"19954","DOI":"10.1016\/S0021-9258(19)88650-7","article-title":"Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides","volume":"267","author":"Monia","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB117","first-page":"604","article-title":"A Phase I trial of ISIS 2503, an antisense inhibitor of H-ras administered by a 24-hour weekly infusion in patients with advanced cancer","volume":"18","author":"Gordon","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB118","first-page":"603","article-title":"Phase I and pharmacokinetic trial of ISIS 2503, a 20-Mer antisense oligonucleotide against H-ras by 14-day continuous infusion in patients with advanced cancer","volume":"18","author":"Dorr","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB119","first-page":"722","article-title":"A phase I trial of ISIS 2503, an antisense inhibitor of H-ras in combination with gemcitabine in patients with advanced cancer","volume":"19","author":"Adjei","year":"2000","journal-title":"Proc ASCO"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB120","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1046\/j.1432-1033.2001.01876.x","article-title":"Aggresome formation by anti-Ras intracellular scFv fragments","volume":"268","author":"Cardinale","year":"2001","journal-title":"Eur J Biochem"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB121","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1046\/j.1432-1327.2000.01125.x","article-title":"Diverting a protein from its cellular location by intracellular antibodies, the case of p21 Ras","volume":"267","author":"Lener","year":"2000","journal-title":"Eur J Biochem"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB122","first-page":"1170","article-title":"Intracellular expression of an antibody fragment-neutralizing p21Ras promotes tumor regression","volume":"58","author":"Cochet","year":"1998","journal-title":"Cancer Res"},{"issue":"13","key":"10.1016\/S0889-8588(02)00050-3_BIB123","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1093\/jnci\/94.13.1031","article-title":"Blocking oncogenic Ras signaling for cancer therapy [letter]","volume":"94","author":"Canevari","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB124","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1358\/dof.2000.025.10.659165","article-title":"Protein farnesyl transferase as a target for the development of anticancer drugs","volume":"25","author":"Adjei","year":"2000","journal-title":"Drugs Future"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB125","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1200\/JCO.1999.17.11.3631","article-title":"Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development","volume":"17","author":"Rowinsky","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB126","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1517\/13543784.9.12.2767","article-title":"Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues","volume":"9","author":"Sebti","year":"2000","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB127","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1021\/tx000138v","article-title":"Biological effects and mechanism of action of farnesyl transferase inhibitors","volume":"13","author":"Ashar","year":"2000","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB128","doi-asserted-by":"crossref","first-page":"30611","DOI":"10.1074\/jbc.270.51.30611","article-title":"Novel tricyclic inhibitors of farnesyl transferase: biochemical characterization and inhibition of Ras modification in transfected Cos cells","volume":"270","author":"Bishop","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB129","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1128\/MCB.20.1.139-148.2000","article-title":"The phosphoinositide 3-OH kinase\/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis","volume":"20","author":"Jiang","year":"2000","journal-title":"Mol Cell Biol"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB130","doi-asserted-by":"crossref","first-page":"30451","DOI":"10.1074\/jbc.M003469200","article-title":"FTIs block the farnesylation of CENP-E and CENP-F, and alter the association of CENP-E with microtubules","volume":"275","author":"Ashar","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB131","doi-asserted-by":"crossref","first-page":"30451","DOI":"10.1074\/jbc.M003469200","article-title":"Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with microtubules","volume":"275","author":"Ashar","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB132","first-page":"131","article-title":"Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro","volume":"61","author":"End","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB133","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1200\/JCO.2000.18.4.927","article-title":"Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer","volume":"18","author":"Zujewski","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB134","first-page":"156a","article-title":"Phase I clinical and pharmacokinetic trial of the farnesyltransferase inhibitor R115777 on a 21-day dosing schedule","volume":"18","author":"Hudes","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB135","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1182\/blood.V97.11.3361","article-title":"Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial","volume":"97","author":"Karp","year":"2001","journal-title":"Blood"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB136","first-page":"316","article-title":"A Phase I pharmacokinetic (PK) and biological study of the farnesyl transferase inhibitor (FTI) R115777 and capecitabine in patients (PTS) with advanced solid malignancies [abstract]","volume":"20","author":"Holden","year":"2001","journal-title":"Proc Annu Meet Am Soc Clin Oncol"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB137","first-page":"5","article-title":"A Phase I and pharmacokinetic study of the farnesyl transferase inhibitor R115777 in combination with Gemcitabine","volume":"19","author":"Patnik","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB138","first-page":"318","article-title":"A Phase I, clinical and pharmacokinetic (PK) trial of the farnesyl transferase inhibitor (FTI) R115777 + Docetaxel: a promising combination in patients (PTS) with solid tumors","volume":"20","author":"Piccart-Gebhart","year":"2001","journal-title":"Proc Annu Meet Am Soc Clin Oncol"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB139","first-page":"318","article-title":"A phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced breast cancer","volume":"19","author":"Johnston","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB140","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1021\/jm980462b","article-title":"(+)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5, 6]cyclohepta[1,2-b]- pyridin-11(R)-yl)-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamid e (SCH-66336): a very potent farnesyl protein transferase inhibitor as a novel antitumor agent","volume":"41","author":"Njoroge","year":"1998","journal-title":"J Med Chem"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB141","first-page":"600","article-title":"Phase I and pharmacologic study of continuous daily oral SCH66336: a novel farnesyl transferase inhibitor, in patients with solid tumors","volume":"18","author":"Eskens","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB142","first-page":"599","article-title":"Phase I and pharmacokinetic study of SCH66336, a novel FPTI, using a 2-week on, 2-week off schedule","volume":"18","author":"Hurwitz","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB143","first-page":"1181","article-title":"A phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity","volume":"60","author":"Adjei","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB144","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1006\/excr.2000.5076","article-title":"The farnesyl transferase inhibitor SCH 66336 induces a G(2) \u2192 M or G(1) pause in sensitive human tumor cell lines","volume":"262","author":"Ashar","year":"2001","journal-title":"Exp Cell Res"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB145","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s002800000170","article-title":"The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo","volume":"46","author":"Shi","year":"2000","journal-title":"Cancer Chemother Pharmacol"},{"issue":"Suppl","key":"10.1016\/S0889-8588(02)00050-3_BIB146","first-page":"403","article-title":"Phase I study of farnesyl transferase inhibitor SCH66336 with paclitaxel in solid tumors: dose finding, pharmacokinetics, efficacy\/safety","volume":"6","author":"Khuri","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB147","first-page":"717","article-title":"Phase I pharmacokinetic trial of the farnesyl transferase inhibitor SCH66336 plus gemcitabine in advanced cancers","volume":"19","author":"Hurwitz","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB148","first-page":"313","article-title":"Phase I study of farnesyl transferase inhibitor, BMS-214662 in solid tumors [abstract]","volume":"20","author":"Kim","year":"2001","journal-title":"Proc Annu Meet Am Soc Clin Oncol"},{"issue":"Suppl","key":"10.1016\/S0889-8588(02)00050-3_BIB149","first-page":"401","article-title":"Pharmacokinetics-antitumor activity relationship of BMS-214662, a novel inhibitor of farnesyltransferase","volume":"6","author":"Lee","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB150","first-page":"720","article-title":"Phase I clinical trial of the farnesyltransferase inhibitor BMS214662 in patients with advanced solid tumors","volume":"19","author":"Ryan","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB151","first-page":"1626","article-title":"A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer","volume":"6","author":"Cunningham","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB152","unstructured":"Sebolt-Leopord J.S. Pfizer: Global research and development. CI-1040: a novel small molecule MEK inhibitor with broad spectrum antitumor activity. Proceedings of the AACR-NCI-EORTC International Conference, abstract #P818. Miami, FL; November 2001."},{"issue":"Suppl","key":"10.1016\/S0889-8588(02)00050-3_BIB153","first-page":"413","article-title":"Phase I and pharmacological study of CCI-779, a cell cycle inhibitor","volume":"6","author":"Hidalgo","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"Suppl","key":"10.1016\/S0889-8588(02)00050-3_BIB154","first-page":"414","article-title":"CCI-779, an ester analogue of rapamycin that interferes with PTEN\/PI3 kinase pathways: a Phase I study utilizing a weekly intravenous schedule","volume":"6","author":"Raymond","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"Suppl","key":"10.1016\/S0889-8588(02)00050-3_BIB155","first-page":"393","article-title":"Effects of geldanamycin on HSP90 cochaperone proteins","volume":"6","author":"Erlichman","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/S0889-8588(02)00050-3_BIB156","article-title":"Phase I study to determine the safety and pharmacokinetics of BAY 43\u20139006 in patients with advanced refractory solid tumors","author":"Hirte","year":"2001"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858802000503?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858802000503?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:33:41Z","timestamp":1760182421000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858802000503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,10]]},"references-count":156,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2002,10]]}},"alternative-id":["S0889858802000503"],"URL":"https:\/\/doi.org\/10.1016\/s0889-8588(02)00050-3","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2002,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibitors of the ras oncogene as therapeutic targets","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S0889-8588(02)00050-3","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2002 Elsevier Science (USA). All rights reserved.","name":"copyright","label":"Copyright"}]}}